Gentian Diagnostics ASA (GENT.OL)
- Previous Close
57.00 - Open
58.00 - Bid 58.00 x --
- Ask 58.40 x --
- Day's Range
57.00 - 61.80 - 52 Week Range
36.60 - 61.80 - Volume
61,702 - Avg. Volume
9,228 - Market Cap (intraday)
848.232M - Beta (5Y Monthly) --
- PE Ratio (TTM)
17.80 - EPS (TTM)
3.09 - Earnings Date --
- Forward Dividend & Yield 0.40 (0.73%)
- Ex-Dividend Date May 7, 2025
- 1y Target Est
67.00
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase. In addition, the company provides faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
www.gentian.comRecent News: GENT.OL
View MorePerformance Overview: GENT.OL
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GENT.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GENT.OL
View MoreValuation Measures
Market Cap
848.23M
Enterprise Value
763.83M
Trailing P/E
17.80
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.51
Price/Book (mrq)
4.17
Enterprise Value/Revenue
5.09
Enterprise Value/EBITDA
26.06
Financial Highlights
Profitability and Income Statement
Profit Margin
30.93%
Return on Assets (ttm)
7.35%
Return on Equity (ttm)
27.55%
Revenue (ttm)
158.07M
Net Income Avi to Common (ttm)
48.89M
Diluted EPS (ttm)
3.09
Balance Sheet and Cash Flow
Total Cash (mrq)
88.74M
Total Debt/Equity (mrq)
2.14%
Levered Free Cash Flow (ttm)
-5.34M